MAI Capital Management
BIB icon

MAI Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

MAI Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250
Closed -$20.4K – 2377
2026
Q1 		$20.4K Hold
250
– – ﹤0.01% 2775
2025
Q4 		$19.9K Hold
250
– – ﹤0.01% 2515
2025
Q3 		$14.9K Hold
250
– – ﹤0.01% 2547
2025
Q2 		$11.5K Hold
250
– – ﹤0.01% 2653
2025
Q1 		$12K Hold
250
– – ﹤0.01% 2413
2024
Q4 		$12.7K Buy
+250
New +$14.8K ﹤0.01% 2410

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $254M AUM 28.38% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
Jump Financial
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Ashton Thomas Private Wealth
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

MAI Capital Management's BIB Position: Q2 2026 in Review

MAI Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2026, closing a stake of 250 shares — an estimated $20.4K sold.

MAI Capital Management first reported a position in BIB in Q4 2024 and held it in 6 quarters. The position peaked at $20.4K in Q1 2026. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • MAI Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 250 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $20.4K.
  • MAI Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $20.4K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.